Corbus Pharmaceuticals
CRBP
86 hedge funds and large institutions have $55.4M invested in Corbus Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 24 increasing their positions, 24 reducing their positions, and 29 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 24
4.63% less ownership
Funds ownership: 89.92% → 85.29% (-4.6%)
13% less funds holding
Funds holding: 99 → 86 (-13)
45% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 29
56% less call options, than puts
Call options by funds: $58K | Put options by funds: $132K
57% less capital invested
Capital invested by funds: $129M → $55.4M (-$73.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
+$2.69M |
| 2 |
EAM
Exome Asset Management
New York
|
+$2.56M |
| 3 |
Renaissance Technologies
New York
|
+$1.82M |
| 4 |
Comerica Bank
Dallas,
Texas
|
+$1.77M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.24M |
| 2 |
ACM
Altium Capital Management
New York
|
-$4.54M |
| 3 |
Millennium Management
New York
|
-$2.52M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$1.97M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.95M |
CRBP Hedge Fund Activity: Q1 2025 in Review
86 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q1 2025, worth a combined $55.4M — down 57% from $129M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of CRBP and 16 opened new positions — a net loss of 13 holders — while 24 trimmed existing stakes and 24 added.
The largest buyer was Prosight Management, adding an estimated $2.69M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $6.24M sold.
- 86 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q1 2025, down from 99 in Q4 2024.
- Funds reported $55.4M of Corbus Pharmaceuticals stock for Q1 2025, down 57% quarter-over-quarter.
- 16 funds opened new Corbus Pharmaceuticals positions in Q1 2025 and 29 closed out, a net change of -13 holders.
- The largest Corbus Pharmaceuticals buyer in Q1 2025 was Prosight Management, an estimated $2.69M added.
- The largest Corbus Pharmaceuticals seller in Q1 2025 was Adage Capital Partners, an estimated $6.24M sold.
Based on aggregated 13F filings for Q1 2025.